ES2188661T3 - Preparacion de un derivado de camptothecin por ciclacion intramolecular. - Google Patents

Preparacion de un derivado de camptothecin por ciclacion intramolecular.

Info

Publication number
ES2188661T3
ES2188661T3 ES95918904T ES95918904T ES2188661T3 ES 2188661 T3 ES2188661 T3 ES 2188661T3 ES 95918904 T ES95918904 T ES 95918904T ES 95918904 T ES95918904 T ES 95918904T ES 2188661 T3 ES2188661 T3 ES 2188661T3
Authority
ES
Spain
Prior art keywords
preparation
camptothecin derivative
chem
intramolecular
cycling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95918904T
Other languages
English (en)
Inventor
Francis Gerard Fang
Edward Mcdonald Huie
Shiping Xie
Daniel L Comins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
OSI Pharmaceuticals LLC
Original Assignee
North Carolina State University
OSI Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University, OSI Pharmaceuticals LLC filed Critical North Carolina State University
Application granted granted Critical
Publication of ES2188661T3 publication Critical patent/ES2188661T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN METODO PARA LA PREPARACION DE CAMPTOTECINA Y COMPUESTOS SIMILARES A CAMPTOTECINA, Y A NUEVOS INTERMEDIARIOS UTILIZADOS EN DICHA PREPARACION. EN PARTICULAR, LA INVENCION PROPORCIONA UN PROCESO PARA LA PREPARACION DE UN DERIVADO DE CAMPTOTECINA DE FORMULA (I), CONOCIDO POR EL NOMBRE QUIMICO "7-(4-METILPIPERACINOMETILENO)-10,11-ETILENDIOXI-20(R,S)-CAMPTOTECINA", QUE COMPRENDE LA CICLACION DEL COMPUESTO DE FORMULA (II''), EN LA QU X ES HALOGENO, PARTICULARMENTE CLORO, BROMO, O YODO; Y DONDE EL COMPUESTO DE FORMULA (I'') SE OBTIENE COMO UNA MEZCLA DE ENANTIOMEROS, RESOLVIENDO OPCIONALMENTE LA MEZCLA PARA OBTENER EL ENANTIOMERO DESEADO; Y/O, SI SE DESEA, CONVIRTIENDO EL CITADO COMPUESTO DE FORMULA (I'') O UNA SAL DEL MISMO, EN UNA SAL O SOLVATO DEL MISMO FISIOLOGICAMENTE ACEPTABLE.
ES95918904T 1994-05-03 1995-05-02 Preparacion de un derivado de camptothecin por ciclacion intramolecular. Expired - Lifetime ES2188661T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/237,081 US5491237A (en) 1994-05-03 1994-05-03 Intermediates in pharmaceutical camptothecin preparation

Publications (1)

Publication Number Publication Date
ES2188661T3 true ES2188661T3 (es) 2003-07-01

Family

ID=22892263

Family Applications (3)

Application Number Title Priority Date Filing Date
ES95918904T Expired - Lifetime ES2188661T3 (es) 1994-05-03 1995-05-02 Preparacion de un derivado de camptothecin por ciclacion intramolecular.
ES02014439T Expired - Lifetime ES2238523T3 (es) 1994-05-03 1995-05-02 Preparacion de un derivado de camptotecina mediante ciclacion intramolecular.
ES95917217T Expired - Lifetime ES2219661T3 (es) 1994-05-03 1995-05-02 Intermedios en al preparacion farmaceutica de camptotecina.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES02014439T Expired - Lifetime ES2238523T3 (es) 1994-05-03 1995-05-02 Preparacion de un derivado de camptotecina mediante ciclacion intramolecular.
ES95917217T Expired - Lifetime ES2219661T3 (es) 1994-05-03 1995-05-02 Intermedios en al preparacion farmaceutica de camptotecina.

Country Status (9)

Country Link
US (4) US5491237A (es)
EP (3) EP0758335B1 (es)
JP (2) JPH09512559A (es)
AT (3) ATE260919T1 (es)
AU (2) AU2465195A (es)
DE (3) DE69534029T2 (es)
DK (1) DK0758335T3 (es)
ES (3) ES2188661T3 (es)
WO (2) WO1995029919A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559309B2 (en) 1996-11-01 2003-05-06 Osi Pharmaceuticals, Inc. Preparation of a camptothecin derivative by intramolecular cyclisation
US6207832B1 (en) * 1999-04-09 2001-03-27 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
EP1488809A1 (en) 2001-01-16 2004-12-22 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer
US6809210B2 (en) 2001-06-12 2004-10-26 Lucent Technologies Inc. Method of solvating a metal in an aromatic organic liquid
US6593334B1 (en) 2002-05-02 2003-07-15 The University Of North Carolina At Chapel Hill Camptothecin-taxoid conjugates as antimitotic and antitumor agents
CZ299329B6 (cs) * 2003-08-26 2008-06-18 Pliva-Lachema A.S. Zpusob výroby 7-ethyl-10-[ 4-(1-piperidino)-1-piperidino]karbonyloxykamptothecinu
CZ299593B6 (cs) * 2003-12-16 2008-09-10 Pliva-Lachema A. S. Zpusob výroby 7-ethyl-10-hydroxykamptothecinu
US8492456B2 (en) * 2004-02-09 2013-07-23 Hewlett-Packard Development Company, L.P. Ink compositions for ink-jet printing
CN101128467B (zh) * 2005-02-22 2010-12-22 霍夫曼-拉罗奇有限公司 喜树碱亚单元的新合成
TWI375678B (en) 2005-06-09 2012-11-01 Yakult Honsha Kk A method of preparation of a tricyclic ketone
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
EA022915B1 (ru) * 2007-10-09 2016-03-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способы лечения острого миелоидного лейкоза и миелодиспластического синдрома
AR074199A1 (es) 2008-11-20 2010-12-29 Glaxosmithkline Llc Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
CN102405047B (zh) 2009-01-30 2014-07-09 葛兰素史密斯克莱有限责任公司 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐
WO2010135504A1 (en) 2009-05-20 2010-11-25 Glaxosmithkline Llc Thiazolopyrimidinone derivatives as pi3 kinase inhibitors
CN101591342B (zh) * 2009-07-03 2011-07-27 华东师范大学 用于喜树碱类化合物制备的关键中间体合成方法
US20110065698A1 (en) 2009-08-26 2011-03-17 Cylene Pharmaceuticals, Inc. Novel protein kinase modulators
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
MY170236A (en) 2010-10-06 2019-07-11 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
JP2015507606A (ja) 2011-11-22 2015-03-12 デシフェラ ファーマシューティカルズ，エルエルシー 抗癌および抗増殖作用を示すピリドンアミドおよび類似体
WO2013113796A1 (en) 2012-01-31 2013-08-08 Smithkline Beecham (Cork) Limited Method of treating cancer
WO2014081718A1 (en) 2012-11-20 2014-05-30 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
PL2925299T3 (pl) 2012-11-30 2018-11-30 Novartis Ag Nowa kompozycja farmaceutyczna
WO2014108837A1 (en) 2013-01-09 2014-07-17 Glaxosmithkline Intellectual Property (No.2) Limited Combination
US20150329524A1 (en) 2013-01-10 2015-11-19 Glaxosmithkline Intellectual Property (No.2) Limited Fatty acid synthase inhibitors
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
US20160361309A1 (en) 2014-02-26 2016-12-15 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
WO2016055935A1 (en) 2014-10-06 2016-04-14 Glaxosmithkline Intellectual Property (No.2) Limited Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
US20180230431A1 (en) 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
JP2019505476A (ja) 2015-12-01 2019-02-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 組合せ処置およびその方法
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
EP3494140A1 (en) 2016-08-04 2019-06-12 GlaxoSmithKline Intellectual Property Development Ltd Anti-icos and anti-pd-1 antibody combination therapy
WO2018100536A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
JP2019529343A (ja) 2017-07-05 2019-10-17 ノバルティス アーゲー 新規な医薬組成物
UY37866A (es) 2017-09-07 2019-03-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
BR112021014662A2 (pt) 2019-02-01 2021-09-21 Glaxosmithkline Intellectual Property Development Limited Tratamentos de combinação para o câncer que compreendem belantamab mafodotin e um anticorpo anti ox40 e usos e métodos dos mesmos
EP3990494A1 (en) 2019-06-26 2022-05-04 GlaxoSmithKline Intellectual Property Development Limited Il1rap binding proteins
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2021046289A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
JP2023512023A (ja) 2020-01-28 2023-03-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 併用療法及びその使用及び方法
CN115073408A (zh) * 2022-08-09 2022-09-20 江苏法安德医药科技有限公司 一种2,3,4,6-四苄基-d-吡喃葡萄糖的合成方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE152774C (es) *
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
DD152774A1 (de) * 1980-08-25 1981-12-09 Brunhilde Gorski Verfahren zur abtrennung von palladium und technetium aus loesungen der kernbrennstoffwiederaufbereitung
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4413118A (en) * 1981-03-02 1983-11-01 Merck & Co., Inc. Process for removal of homogeneous catalyst group VIII metals from process streams
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
DE3682874D1 (de) * 1985-10-21 1992-01-23 Daiichi Seiyaku Co Pyranoindolizinderivate und verfahren zu ihrer herstellung.
JPS6314824A (ja) * 1986-07-04 1988-01-22 Tanaka Kikinzoku Kogyo Kk 貴金属元素の回収方法
JPS6333355A (ja) * 1986-07-29 1988-02-13 Mitsui Toatsu Chem Inc シスチンの精製方法
US5244903A (en) * 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US4981968A (en) * 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5053512A (en) * 1987-04-14 1991-10-01 Research Triangle Institute Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US5227380A (en) * 1987-03-31 1993-07-13 Research Triangle Institute Pharmaceutical compositions and methods employing camptothecins
US5122526A (en) * 1987-03-31 1992-06-16 Research Triangle Institute Camptothecin and analogs thereof and pharmaceutical compositions and method using them
US4894456A (en) * 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5106742A (en) * 1987-03-31 1992-04-21 Wall Monroe E Camptothecin analogs as potent inhibitors of topoisomerase I
US5122606A (en) * 1987-04-14 1992-06-16 Research Triangle Institute 10,11-methylenedioxy camptothecins
US5180722A (en) * 1987-04-14 1993-01-19 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
US5049668A (en) * 1989-09-15 1991-09-17 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin analogs
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
US5260461A (en) * 1988-01-11 1993-11-09 Massachusetts Institute Of Technology Ligands for ADH: cinchona alkaloids and moderately sized organic substituents linked through a planar aromatic spacer group
ATE128449T1 (de) * 1988-01-11 1995-10-15 Massachusetts Inst Technology Durch komplexmittel beschleunigte katalytische asymmetrische dihydroxylierung.
US5227543A (en) * 1988-01-11 1993-07-13 Massachusetts Institute Of Technology Facilitation of turnover in the ADH by additives which catalyze the hydrolysis of the OS(VI) glycolate esters
US4965364A (en) * 1988-02-23 1990-10-23 Massachusetts Institute Of Technology Ligand-accelerated catalytic asymmetric dihydroxylation
US5126494A (en) * 1988-01-11 1992-06-30 Massachusetts Institute Of Technology Methods for catalytic asymmetric dihydroxylation of olefins
US4871855A (en) * 1988-01-11 1989-10-03 Massachusetts Institute Of Technology Ligand-accelerated catalytic asymmetric dihydroxylation using dihydroquinidine and dihydroquinidine esters as ligands
JPH0615547B2 (ja) * 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
DK0418099T3 (da) * 1989-09-15 2002-04-02 Res Triangle Inst Fremgangsmåde til fremstilling af 10,11-methylendioxy-20(RS)-camptothecin og 10,11-methylendioxy-20(S)-camptothecinanaloger
US5099047A (en) * 1989-11-17 1992-03-24 Mitsubishi Kasei Corporation Method for recovering a group viii metal solid complex and hydroformylation method
IE913790A1 (en) * 1990-10-31 1992-05-22 Smithkline Beecham Corp SUBSTITUTED INDOLIZINO [1,2-b]QUINOLINONES
US5258516A (en) * 1990-12-20 1993-11-02 Nc State University Optically pure D,E ring intermediates useful for the synthesis of camptothecin and camptothecin analogs
US5200524A (en) * 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5212317A (en) * 1990-12-20 1993-05-18 North Carolina State University Methods and intermediates for the assymmetric synthesis of camptothecin and camptothecin analogs
US5247089A (en) * 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5162532A (en) * 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5191082A (en) * 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5315007A (en) * 1990-12-20 1994-05-24 North Carolina State University Process for making DE ring intermediates for the synthesis of camptothecin and camptothecin analogs
US5254690A (en) * 1990-12-20 1993-10-19 North Carolina State University Alkoxymethylpyridine d-ring intermediates useful for the synthesis of camptpthecin and camptothecin analogs
US5264579A (en) * 1990-12-20 1993-11-23 North Carolina State University D ring intermediates for the synthesis of camptothecin and camptothecin analogs
US5243050A (en) * 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
CA2087035C (en) * 1991-05-13 2004-10-05 K. Barry Sharpless Heterocyclic chiral ligands and method for catalytic asymmetric dihydroxylation of olefins
EP0540099B1 (en) * 1991-10-29 1996-04-17 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
CA2087898A1 (en) * 1992-01-24 1993-07-25 Hiroshi Akimoto Condensed heterocyclic compounds, their production and use
WO1993016698A1 (en) * 1992-02-21 1993-09-02 Smithkline Beecham Corporation SUBSTITUTED FURO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLINONES
CA2142831A1 (en) * 1992-08-21 1994-03-03 Arthur B. Pardee Treatment of human viral infections
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5479108A (en) * 1992-11-25 1995-12-26 David Cheng Method and apparatus for handling wafers
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
JP3499246B2 (ja) * 1995-11-02 2004-02-23 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド カンプトテシン誘導体の製造法

Also Published As

Publication number Publication date
ATE260919T1 (de) 2004-03-15
DE69532634D1 (de) 2004-04-08
AU2381695A (en) 1995-11-29
US5840898A (en) 1998-11-24
EP0758335A1 (en) 1997-02-19
WO1995029919A1 (en) 1995-11-09
ATE227292T1 (de) 2002-11-15
JPH09512559A (ja) 1997-12-16
EP1254908B1 (en) 2005-02-23
EP1254908B9 (en) 2005-09-21
EP0758333A1 (en) 1997-02-19
AU2465195A (en) 1995-11-29
WO1995029917A2 (en) 1995-11-09
US5491237A (en) 1996-02-13
EP1254908A1 (en) 2002-11-06
WO1995029917A3 (en) 1995-12-28
JPH09512558A (ja) 1997-12-16
DE69534029D1 (de) 2005-03-31
EP0758335B1 (en) 2002-11-06
DK0758335T3 (da) 2003-03-17
HK1052687A1 (en) 2003-09-26
EP0758333B1 (en) 2004-03-03
ES2219661T3 (es) 2004-12-01
US6462196B1 (en) 2002-10-08
ATE289608T1 (de) 2005-03-15
DE69528762D1 (de) 2002-12-12
US6063923A (en) 2000-05-16
DE69534029T2 (de) 2006-01-12
DE69532634T2 (de) 2005-03-10
DE69528762T2 (de) 2003-07-17
ES2238523T3 (es) 2005-09-01

Similar Documents

Publication Publication Date Title
ES2188661T3 (es) Preparacion de un derivado de camptothecin por ciclacion intramolecular.
NO303574B1 (no) Ny fremgangsmÕte for fremstilling av 9-amino-6-demetyl-6-deoksytetracykliner
HUT52043A (en) Process for producing intermediates for producing substituted indolinon derivatives
IN167606B (es)
ES2145920T3 (es) Procedimiento de produccion de derivado de alcoxiiminoacetamida.
ATE245147T1 (de) Substituierte aminochinazolinon (thion) derivate
DK0662475T3 (da) Fremgangsmåde til fremstilling af 2-perfluoralkyl-3-oxazolin-5-on.
ATE311382T1 (de) Verfahren zur herstellung von 2-carbamoyl- pyridinen
DE69733716D1 (de) Verfahren zur herstellung von imidazolderivaten
ES2164258T3 (es) Procedimiento de preparacion de derivados de carbamoilmetilurea.
HU0204401D0 (en) Process for producing 2,6-dichlorophenol derivatives
ATE244228T1 (de) Verfahren zur herstellung von chloroacetylaminothiazoleaceticsäure derivate
IL135533A (en) Process for preparing a 1,1,1-trifluoro-2-aminoalkane
PT84067B (pt) Processo de preparacao de novos derivados de pregnano